Canada Spends Logo

Explorez notre analyse du budget 2026

Grant: CIHR Fellowship

University of Toronto

$135,000.00

Re-sensitization of immune checkpoint therapy resistant cancers to cytotoxic T-lymphocyte mediated killing

EF 2019-20

Résumé
Cytotoxic T-lymphocytes have a key role in elimination of cancer cells by the immune system, but their anti-cancer efficacy is severely hampered by immune checkpoints. Immune checkpoint inhibition (ICI) can re-activate anti-cancer immunity and provides durable responses in multiple cancer types. Unfortunately, clinical studies indicate that the majority of cancers do not durably respond due to initial or acquired resistance. Loss of TNF signaling was recently identified as a determinant of ICI resistance. Preliminary work by the Moffat lab identified the TNFa-responsive membrane receptor Tnfrsf1a as a top resistance hit in multiple cancer models. Importantly, it is currently unknown how to re-sensitize cancers with resistance mutations like TNFRSF1A to elimination by cytotoxic T-lymphocytes after ICI therapy. Therefore, I aim to uncover genetic vulnerabilities in TNFRSF1A mutant cancers by performing genome-wide CRISPR screens in Tnfrsf1a-knockout cancer cells treated with cytotoxic T-lymphocytes followed by in vitro and in vivo validation of candidate targets. By determining changes in cancer immune infiltration, through various single-cell RNA sequencing techniques, I aim to get a mechanistic understanding of the immunological consequences of TNFRSF1A loss. Collectively, these strategies will provide new therapeutic targets that can aid to re-sensitize patients who developed ICI resistance through TNFRSF1A mutations.
Programme
CIHR Fellowship
Bénéficiaire
Emplacement
Ontario, Canada
Type de bénéficiaire
Academia
Type
Grant
Source
CIHR Funding Decisions Database

Tel que publié

Id
412967
Name
Caumanns Joseph J
Region
Ontario
Country
Canada
Orgtype
Institution Paid; Research Institution
Instname2
Cancer Research
Theme2
Biomedical
Prcname2
Fellowships - Post-PhD
Projecttitle
Re-sensitization of immune checkpoint therapy resistant cancers to cytotoxic T-lymphocyte mediated killing
Programtype2
Fellowship Programs
Orgnameinp2
University of Toronto
Cihramount2
$135,000
Cihrequipment2
$0
Programname2
CIHR Fellowship
Keyworddelim
Cancer Immune Resistance; Crispr Screens; Immunotherapy; Single-Cell Rna Sequencing; Tnf Receptor
Abstract
Cytotoxic T-lymphocytes have a key role in elimination of cancer cells by the immune system, but their anti-cancer efficacy is severely hampered by immune checkpoints. Immune checkpoint inhibition (ICI) can re-activate anti-cancer immunity and provides durable responses in multiple cancer types. Unfortunately, clinical studies indicate that the majority of cancers do not durably respond due to initial or acquired resistance. Loss of TNF signaling was recently identified as a determinant of ICI resistance. Preliminary work by the Moffat lab identified the TNFa-responsive membrane receptor Tnfrsf1a as a top resistance hit in multiple cancer models. Importantly, it is currently unknown how to re-sensitize cancers with resistance mutations like TNFRSF1A to elimination by cytotoxic T-lymphocytes after ICI therapy. Therefore, I aim to uncover genetic vulnerabilities in TNFRSF1A mutant cancers by performing genome-wide CRISPR screens in Tnfrsf1a-knockout cancer cells treated with cytotoxic T-lymphocytes followed by in vitro and in vivo validation of candidate targets. By determining changes in cancer immune infiltration, through various single-cell RNA sequencing techniques, I aim to get a mechanistic understanding of the immunological consequences of TNFRSF1A loss. Collectively, these strategies will provide new therapeutic targets that can aid to re-sensitize patients who developed ICI resistance through TNFRSF1A mutations.
Competitiondate
201910
Approvedterm2
3 yrs 0 mth
Pinamesdelim
Caumanns, Joseph J
Approvedterm
3 ans 0 mois
Cihrcontribution2
~ $135,000~ $0~